A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia)
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 10 Jun 2013 Planned end date changed from 1 Aug 2019 to 1 Sep 2020 as reported by ClinicalTrials.gov.
- 12 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.